Toreforant, a histamine H4 receptor antagonist, in patients with active rheumatoid arthritis despite methotrexate therapy: Results of 2 phase II studies

Robin L. Thurmond, Andrew Greenspan, Waldemar Radziszewski, Xie L. Xu, Ye Miao, Bin Chen, Ting Ting Ge, Bei Zhou, Daniel G. Baker, Dace Pavlova, Christopher T. Ritchlin, Yoshiya Tanaka, Tsutomu Takeuchi, Josef S. Smolen

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objective. To assess toreforant (selective histamine H4 receptor antagonist) in active rheumatoid arthritis (RA). Methods. In a phase IIa, double-blind, placebo-controlled test, 86 patients were randomized (2:1) to once-daily toreforant 100 mg or placebo for 12 weeks. In phase IIb, double-blind, placebo-controlled, dose-range-finding evaluations, 272 patients were randomized (1:1:1:1) to once-daily placebo or toreforant 3/10/30 mg. Primary efficacy endpoints for both studies were Week 12 changes in 28-joint Disease Activity Score-C-reactive protein (DAS28-CRP). Results. Phase IIa testing was terminated prematurely (patient fatality; secondary hemophagocytic lymphohistiocytosis). Posthoc analyses indicated toreforant 100 mg/day reduced RA signs/symptoms through Week 12. Phase IIb testing, however, showed no significant Week 12 improvement in DAS28-CRP with toreforant. Conclusion. Toreforant was not effective in phase IIb testing.

Original languageEnglish
Pages (from-to)1637-1642
Number of pages6
JournalJournal of Rheumatology
Volume43
Issue number9
DOIs
Publication statusPublished - 2016 Sep 1

Fingerprint

Histamine Receptors
Methotrexate
Rheumatoid Arthritis
Placebos
Hemophagocytic Lymphohistiocytosis
Joint Diseases
Therapeutics
C-Reactive Protein
Signs and Symptoms

Keywords

  • Clinical trial
  • Histamine H receptor antagonist
  • Methotrexate
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology

Cite this

Toreforant, a histamine H4 receptor antagonist, in patients with active rheumatoid arthritis despite methotrexate therapy : Results of 2 phase II studies. / Thurmond, Robin L.; Greenspan, Andrew; Radziszewski, Waldemar; Xu, Xie L.; Miao, Ye; Chen, Bin; Ge, Ting Ting; Zhou, Bei; Baker, Daniel G.; Pavlova, Dace; Ritchlin, Christopher T.; Tanaka, Yoshiya; Takeuchi, Tsutomu; Smolen, Josef S.

In: Journal of Rheumatology, Vol. 43, No. 9, 01.09.2016, p. 1637-1642.

Research output: Contribution to journalArticle

Thurmond, RL, Greenspan, A, Radziszewski, W, Xu, XL, Miao, Y, Chen, B, Ge, TT, Zhou, B, Baker, DG, Pavlova, D, Ritchlin, CT, Tanaka, Y, Takeuchi, T & Smolen, JS 2016, 'Toreforant, a histamine H4 receptor antagonist, in patients with active rheumatoid arthritis despite methotrexate therapy: Results of 2 phase II studies', Journal of Rheumatology, vol. 43, no. 9, pp. 1637-1642. https://doi.org/10.3899/jrheum.160164
Thurmond, Robin L. ; Greenspan, Andrew ; Radziszewski, Waldemar ; Xu, Xie L. ; Miao, Ye ; Chen, Bin ; Ge, Ting Ting ; Zhou, Bei ; Baker, Daniel G. ; Pavlova, Dace ; Ritchlin, Christopher T. ; Tanaka, Yoshiya ; Takeuchi, Tsutomu ; Smolen, Josef S. / Toreforant, a histamine H4 receptor antagonist, in patients with active rheumatoid arthritis despite methotrexate therapy : Results of 2 phase II studies. In: Journal of Rheumatology. 2016 ; Vol. 43, No. 9. pp. 1637-1642.
@article{fbce929590d8432781c36161d429f2dd,
title = "Toreforant, a histamine H4 receptor antagonist, in patients with active rheumatoid arthritis despite methotrexate therapy: Results of 2 phase II studies",
abstract = "Objective. To assess toreforant (selective histamine H4 receptor antagonist) in active rheumatoid arthritis (RA). Methods. In a phase IIa, double-blind, placebo-controlled test, 86 patients were randomized (2:1) to once-daily toreforant 100 mg or placebo for 12 weeks. In phase IIb, double-blind, placebo-controlled, dose-range-finding evaluations, 272 patients were randomized (1:1:1:1) to once-daily placebo or toreforant 3/10/30 mg. Primary efficacy endpoints for both studies were Week 12 changes in 28-joint Disease Activity Score-C-reactive protein (DAS28-CRP). Results. Phase IIa testing was terminated prematurely (patient fatality; secondary hemophagocytic lymphohistiocytosis). Posthoc analyses indicated toreforant 100 mg/day reduced RA signs/symptoms through Week 12. Phase IIb testing, however, showed no significant Week 12 improvement in DAS28-CRP with toreforant. Conclusion. Toreforant was not effective in phase IIb testing.",
keywords = "Clinical trial, Histamine H receptor antagonist, Methotrexate, Rheumatoid arthritis",
author = "Thurmond, {Robin L.} and Andrew Greenspan and Waldemar Radziszewski and Xu, {Xie L.} and Ye Miao and Bin Chen and Ge, {Ting Ting} and Bei Zhou and Baker, {Daniel G.} and Dace Pavlova and Ritchlin, {Christopher T.} and Yoshiya Tanaka and Tsutomu Takeuchi and Smolen, {Josef S.}",
year = "2016",
month = "9",
day = "1",
doi = "10.3899/jrheum.160164",
language = "English",
volume = "43",
pages = "1637--1642",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "9",

}

TY - JOUR

T1 - Toreforant, a histamine H4 receptor antagonist, in patients with active rheumatoid arthritis despite methotrexate therapy

T2 - Results of 2 phase II studies

AU - Thurmond, Robin L.

AU - Greenspan, Andrew

AU - Radziszewski, Waldemar

AU - Xu, Xie L.

AU - Miao, Ye

AU - Chen, Bin

AU - Ge, Ting Ting

AU - Zhou, Bei

AU - Baker, Daniel G.

AU - Pavlova, Dace

AU - Ritchlin, Christopher T.

AU - Tanaka, Yoshiya

AU - Takeuchi, Tsutomu

AU - Smolen, Josef S.

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Objective. To assess toreforant (selective histamine H4 receptor antagonist) in active rheumatoid arthritis (RA). Methods. In a phase IIa, double-blind, placebo-controlled test, 86 patients were randomized (2:1) to once-daily toreforant 100 mg or placebo for 12 weeks. In phase IIb, double-blind, placebo-controlled, dose-range-finding evaluations, 272 patients were randomized (1:1:1:1) to once-daily placebo or toreforant 3/10/30 mg. Primary efficacy endpoints for both studies were Week 12 changes in 28-joint Disease Activity Score-C-reactive protein (DAS28-CRP). Results. Phase IIa testing was terminated prematurely (patient fatality; secondary hemophagocytic lymphohistiocytosis). Posthoc analyses indicated toreforant 100 mg/day reduced RA signs/symptoms through Week 12. Phase IIb testing, however, showed no significant Week 12 improvement in DAS28-CRP with toreforant. Conclusion. Toreforant was not effective in phase IIb testing.

AB - Objective. To assess toreforant (selective histamine H4 receptor antagonist) in active rheumatoid arthritis (RA). Methods. In a phase IIa, double-blind, placebo-controlled test, 86 patients were randomized (2:1) to once-daily toreforant 100 mg or placebo for 12 weeks. In phase IIb, double-blind, placebo-controlled, dose-range-finding evaluations, 272 patients were randomized (1:1:1:1) to once-daily placebo or toreforant 3/10/30 mg. Primary efficacy endpoints for both studies were Week 12 changes in 28-joint Disease Activity Score-C-reactive protein (DAS28-CRP). Results. Phase IIa testing was terminated prematurely (patient fatality; secondary hemophagocytic lymphohistiocytosis). Posthoc analyses indicated toreforant 100 mg/day reduced RA signs/symptoms through Week 12. Phase IIb testing, however, showed no significant Week 12 improvement in DAS28-CRP with toreforant. Conclusion. Toreforant was not effective in phase IIb testing.

KW - Clinical trial

KW - Histamine H receptor antagonist

KW - Methotrexate

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=84985015790&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84985015790&partnerID=8YFLogxK

U2 - 10.3899/jrheum.160164

DO - 10.3899/jrheum.160164

M3 - Article

C2 - 27422891

AN - SCOPUS:84985015790

VL - 43

SP - 1637

EP - 1642

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 9

ER -